Generic Veltassa Availability
Last updated on Apr 10, 2025.
Veltassa is a brand name of patiromer, approved by the FDA in the following formulation(s):
VELTASSA (patiromer sorbitex calcium - powder;oral)
-
Manufacturer: VIFOR PHARMA
Approval date: October 21, 2015
Strength(s): EQ 8.4GM BASE/PACKET [RLD], EQ 16.8GM BASE/PACKET [RLD], EQ 25.2GM BASE/PACKET (discontinued) [RLD] -
Manufacturer: VIFOR PHARMA
Approval date: October 2, 2023
Strength(s): EQ 1GM BASE/PACKET [RLD]
Is there a generic version of Veltassa available?
No. There is currently no therapeutically equivalent version of Veltassa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Veltassa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Potassium-binding agents for treating hypertension and hyperkalemia
Patent 11,123,363
Issued: September 21, 2021
Inventor(s): Klaerner Gerrit & Berman Lance
Assignee(s): VIFOR (INTERNATIONAL) LTD.The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
Patent expiration dates:
- October 8, 2033✓
- October 8, 2033
-
Ion binding polymers and uses thereof
Patent 7,556,799
Issued: July 7, 2009
Inventor(s): Charmot; Dominique et al.
Assignee(s): Relypsa, Inc. (Santa Clara, CA)The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Patent expiration dates:
- February 27, 2025✓
- February 27, 2025
-
Methods and compositions for treatment of ion imbalances
Patent 8,147,873
Issued: April 3, 2012
Inventor(s): Charmot Dominique & Liu Mingjun
Assignee(s): Relypsa, Inc.The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
Patent expiration dates:
- June 20, 2028✓
- June 20, 2028
-
Ion binding polymers and uses thereof
Patent 8,216,560
Issued: July 10, 2012
Inventor(s): Charmot Dominique & Chang Han Ting & Fordtran John & Klaerner Gerrit & Buysse Jerry M. & Alpern Robert & Liu Mingjun
Assignee(s): Relypsa, Inc.The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Patent expiration dates:
- March 14, 2027✓
- March 14, 2027
-
Ion binding polymers and uses thereof
Patent 8,282,913
Issued: October 9, 2012
Inventor(s): Charmot Dominique & Chang Han-Ting & Liu Mingjun & Klaerner Gerrit
Assignee(s): Relypsa, Inc.The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Patent expiration dates:
- May 29, 2027✓
- May 29, 2027
-
Linear polyol stabilized polyfluoroacrylate compositions
Patent 8,337,824
Issued: December 25, 2012
Inventor(s): Albrecht Detlef & Burdick Michael & Chang Han-Ting & Charmot Dominique & Chidambaram Ramakrishnan & Connor Eric & Halfon Sherin & Huang I-Zu & Liu Mingjun & Mills Jonathan & Strüver Werner
Assignee(s): Relypsa, Inc.The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.
Patent expiration dates:
- May 29, 2030✓✓
- May 29, 2030
-
Potassium-binding agents for treating hypertension and hyperkalemia
Patent 9,492,476
Issued: November 15, 2016
Inventor(s): Klaerner Gerrit & Berman Lance
Assignee(s): Relypsa, Inc.The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
Patent expiration dates:
- October 8, 2033✓
- October 8, 2033
-
Potassium-binding agents for treating hypertension and hyperkalemia
Patent 9,925,212
Issued: March 27, 2018
Inventor(s): Klaerner Gerrit & Berman Lance
Assignee(s): Relypsa, Inc.The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
Patent expiration dates:
- October 8, 2033✓
- October 8, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 2, 2026 - NEW PATIENT POPULATION
- October 2, 2026 - NEW STRENGTH
More about Veltassa (patiromer)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (12)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: cation exchange resins
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.